Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyBluecross Idaho Omidubicel Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy 8.01.568

    Omidubicel as Adjunct Treatment for Hematologic Malignancies

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 8.01.568 alerts

    Get alerted when Policy 8.01.568 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage policy addressing omidubicel for individuals with hematologic malignancies planning myeloablative allogeneic umbilical cord blood transplantation; use in this setting is considered investigational.

    Policy Summary
    PayerBluecross Idaho
    PolicyOmidubicel as Adjunct Treatment for Hematologic Malignancies
    Policy CodePolicy N/A
    Change TypeAnnual reviewno material clinical or coverage change
    Effective DateNov 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateN/A
    Key ActionTreatment should be supervised by a physician experienced in hematologic malignancies at a center with hematopoietic stem cell transplantation expertise.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was replaced on November 19, 2026, with updated references and no change to the policy statements.

    InvestigationalPolicy stance
    Age 12+FDA approval population
    10 vs 20.5 daysNeutrophil engraftment
    55% vs 35%Day-42 platelet engraftment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    125 participantsPivotal trial population

    Coverage Criteria

    Myeloablative Allogeneic Umbilical Cord Transplantation

    Considered investigational when all of the following apply:

    Investigational omidubicel use

    • The individual has a hematologic malignancy and is planning myeloablative allogeneic umbilical cord transplantation.

      Omidubicel is considered investigational in this setting.

    Covered Regimens and Clinical Context

    RegimenClinical setting / indicationCoverage status
    Omidubicel (omidubicel-onlv; Omisirge) as an adjunct to umbilical cord blood transplantationHematologic malignancies in individuals planning myeloablative allogeneic umbilical cord blood transplantationInvestigational
    RegimenClinical setting / indicationCoverage status
    Omidubicel used with allogeneic umbilical cord blood transplantationHematologic malignancies in patients undergoing umbilical cord blood transplantation after myeloablative conditioning, particularly when a matched sibling or unrelated donor is not readily availableNeutral
    RegimenClinical setting / indicationCoverage status
    Standard unmanipulated umbilical cord blood transplantationComparison regimen in the pivotal randomized trialNeutral
    RegimenClinical setting / indicationCoverage status
    Omidubicel-onlvRecipient of umbilical cord blood undergoing a planned myeloablative conditioning regimenCovered
    RegimenClinical setting / indicationCoverage status
    OmidubicelAdjunct treatment for hematologic malignancies in individuals planning myeloablative allogeneic umbilical cord transplantationExperimental

    Coding Information

    CPTCPT
    N/A
    HCPCSHCPCS
    J3490Unclassified drugs (no specified code)
    ICD-10-CMICD-10
    C81.00-C81.99Hodgkin lymphoma code range
    C82.00-C82.99Follicular lymphoma code range
    C83.00-C83.99Non-Follicular lymphoma code range
    C84.00-C84.99Mature T/NK lymphomas code range
    C85.10-C85.99Other specified and unspecified non-Hodgkin lymphoma code range
    C86.0-C86.6Other specified type of T/NK lymphomas code range
    C88.0-C88.9Malignant immunoproliferative diseases and certain other B-cell lymphomas code range
    C90.00-C90.32Multiple myelomas & malignant plasma cell neoplasm code range
    C91.00-C91.92Lymphoid leukemia code range
    C92.00-C92.92Lymphoid leukemia code range; Myeloid leukemia code range
    1–10 of 13
    1/2
    ICD-10-PCSICD-10
    C95.00-C95.92Codes only apply to inpatient services

    Provider Actions and Coverage Status

    Note

    Specialist Supervision and Safety Monitoring

    Treatment should be provided under the supervision of a physician experienced in hematologic malignancies at a center with expertise in hematopoietic stem cell transplantation. Monitor closely for serious or fatal complications and manage them promptly according to product labeling.

    • Infusion reactions: Monitor during infusion and discontinue omidubicel for severe reactions. Use is contraindicated in individuals with a known allergy to dimethyl sulfoxide, Dextran 40, gentamicin, human serum albumin, or bovine material.
    • Graft-versus-host disease (GVHD): Fatal GVHD may occur; immunosuppressive therapy may reduce the risk.
    • Engraftment syndrome: Fatal engraftment syndrome may occur; treat promptly with corticosteroids.
    • Graft failure: Monitor for hematopoietic recovery using laboratory evidence.
    Denial Risk

    Investigational Transplant Use

    Omidubicel is considered investigational for individuals with hematologic malignancies planning myeloablative allogenic umbilical cord transplantation.

    Clinical Background

    Hematopoietic cell transplantation restores bone marrow and immune function after marrow-toxic cytotoxic therapy, with or without total-body radiotherapy. The infused hematopoietic stem cells may come from the patient (autologous transplantation) or a donor (allogeneic transplantation), and may be collected from bone marrow, peripheral blood, or umbilical cord blood.

    Umbilical cord blood transplantation uses blood remaining in the umbilical cord and placenta after birth as an allogeneic source of hematopoietic stem and progenitor cells. It may be used when an HLA-matched related or unrelated donor is unavailable, although delayed engraftment, graft failure, infectious complications, and limited cell doses remain relevant clinical considerations. Omidubicel is an ex vivo expanded product derived from a single allogeneic cord blood unit and is designed to accelerate neutrophil recovery and reduce infection risk; Omisirge (omidubicel-onlv) received FDA approval in April 2023 for adults and pediatric patients 12 years and older with hematologic malignancies undergoing cord blood transplantation after myeloablative conditioning.

    Definitions and Abbreviations

    Hematopoietic Cell Transplantation
    DefinitionA procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function.
    Clinical contextUsed after bone marrow-toxic doses of cytotoxic drugs, with or without whole-body radiotherapy.
    Cell sourceStem cells may come from the transplant recipient or a donor and may be harvested from bone marrow, peripheral blood, or umbilical cord blood.
    Umbilical Cord Blood Transplantation
    DefinitionA transplant using blood remaining in the umbilical cord and placenta following birth.
    Cell sourceThe blood provides hematopoietic stem and progenitor cells for allogeneic transplantation.
    Policy Summary
    PayerBluecross Idaho
    PolicyOmidubicel as Adjunct Treatment for Hematologic Malignancies
    Policy CodePolicy N/A
    Change TypeAnnual reviewno material clinical or coverage change
    Effective DateNov 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateN/A
    Key ActionTreatment should be supervised by a physician experienced in hematologic malignancies at a center with hematopoietic stem cell transplantation expertise.
    SourceLink
    On This Page
    Coverage CriteriaCovered Regimens and Clinical ContextCoding InformationProvider Actions and Coverage StatusClinical BackgroundDefinitions and Abbreviations
    Denial Risk

    Current Policy Status

    The current policy status remains unchanged: omidubicel is investigational for hematologic malignancies in the specified myeloablative allogenic umbilical cord transplantation setting. The policy was reaffirmed during the 11/19/2026 annual review, with references updated.

    Typical useUsed for individuals who lack an HLA-matched related or unrelated donor.
    Omidubicel
    ProductA blood-based stem cell therapy derived from a single allogeneic umbilical cord blood unit.
    Cellular technologyUses proprietary expansion technology based on nicotinamide.
    Intended cellular effectThe technology is proposed to enable donor cells to grow while maintaining functionality, increasing homing to the recipient’s bone marrow and retaining engraftment capacity.
    UCB Transplantation
    DefinitionUmbilical cord blood transplantation uses umbilical cord blood as a source of allogeneic hematopoietic stem cells.
    Relevant populationThe relevant population includes individuals 12 years of age or older with hematologic malignancies planning UCB transplantation after myeloablative conditioning.
    Clinical useUCB transplantation is typically reserved for patients without an HLA-matched donor and should be performed at centers with expertise in the procedure.
    Allogeneic HSCT
    DefinitionAllogeneic hematopoietic stem cell transplantation performed after myeloablative conditioning.
    Transplant settingThe pivotal trial included patients with high-risk hematologic malignancies who were candidates for myeloablative allogeneic HSCT.
    Donor contextParticipants did not have a readily available matched sibling or unrelated donor and had a UCB unit matched at 4 or more loci.
    GVHD
    DefinitionGraft-versus-host disease is an adverse outcome assessed after transplantation.
    Acute GVHDThe pivotal trial reported acute grade 2 to 4 GVHD at 100 days after transplantation.
    Comparative contextRates of acute and chronic GVHD were similar between omidubicel and standard umbilical cord blood transplantation groups in the pivotal trial.
    Omidubicel Treatment Option
    Treatment purposeOmidubicel is intended to provide a treatment option for patients lacking a matched sibling or matched unrelated donor source.
    Transplant settingThe intended setting is umbilical cord blood transplantation after myeloablative conditioning.
    Disease populationThe treatment is intended for patients with hematologic malignancies.
    UCB
    AbbreviationUCB
    MeaningUmbilical cord blood.
    Clinical useUCB is used as a source of hematopoietic stem cells for transplantation.
    EAP
    AbbreviationEAP
    MeaningExpanded access program.
    Evidence contextThe policy reports outcomes for an omidubicel expanded access program cohort.
    aGVHD
    AbbreviationaGVHD
    MeaningAcute graft-versus-host disease.
    Clinical contextAcute GVHD is an outcome reported in studies of omidubicel after transplantation.
    DFS
    AbbreviationDFS
    MeaningDisease-free survival.
    Evidence contextDFS was reported as an outcome in studies evaluating omidubicel after transplantation.
    OS
    AbbreviationOS
    MeaningOverall survival.
    Evidence contextOS was reported as an outcome in studies evaluating omidubicel after transplantation.